Education
About Us
Working with TipRanks
Follow Us
Cormedix (CRMD)
NASDAQ:CRMD
CRMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.87 - $17.43
Previous CloseN/A
Volume1.29M
Average Volume (3M)2.73M
Market Cap
$974.92M
Enterprise Value$695.76M
Total Cash (Recent Filing)$190.71B
Total Debt (Recent Filing)$435.25K
Price to Earnings (P/E)18.1
Beta1.72
Next Earnings
Nov 06, 2025EPS Estimate
0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding74,648,994
10 Day Avg. Volume4,501,706
30 Day Avg. Volume2,725,749
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue5.73
Enterprise Value/Gross Profit5.99
Enterprise Value/Ebitda13.30
Forecast
1Y Price Target
$19.50Price Target Upside43.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCorMedix delivered 2Q25 financial results with total revenues of $39.7M for DefenCath, which was above expectations and is likely appreciated by investors.
Product ExpansionRezzayo's potential expanded indication in adult allogenic blood and marrow transplant patients could drive meaningful upside for CorMedix.
Strategic AcquisitionThe acquisition of Melinta Therapeutics is viewed positively due to significant synergies and the potential to unlock greater hospital and acute care revenue.
Bears Say
Debt And Guidance ConcernsShares are down, partly driven by technical issues around the convertible debt and some disappointment with DefenCath's guidance.
Market SentimentInvestor caution around the anti-infective space likely resulted in a stock reaction of a decrease in value compared to the market.
Reimbursement RiskThe biggest risk to the company's story is the TDAPA reimbursement starting in July 2026.
Cormedix News
CRMD FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was $4.87 and its highest was $17.43 in the past 12 months.
What is Cormedix’s market cap?
Cormedix’s market cap is $974.92M.
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is Nov 06, 2025 which is in 75 days.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Aug 07, 2025. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.187 by $0.103.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is 0.3.
How many shares outstanding does Cormedix have?
Cormedix has 74,648,994 shares outstanding.
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of $0.29 in its last earnings report, beating expectations of $0.187. Following the earnings report the stock price went down -9.54%.
Which hedge fund is a major shareholder of Cormedix?
Currently, no hedge funds are holding shares in CRMD
Cormedix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.50 (43.81% Upside)
$19.50 (43.81% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.4%
Last 30 Days ▲ 13.8%
Last 30 Days ▲ 13.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
169.32%
12-Months-Change
Fundamentals
Return on Equity
38.35%
Trailing 12-Months
Asset Growth
337.55%
Trailing 12-Months
Company Description
Cormedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company operates in the healthcare sector and its core product is DefenCath, an antibacterial and antifungal solution designed to prevent catheter-related bloodstream infections in patients undergoing hemodialysis.
CRMD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant strategic progress through the acquisition of Melinta, strong financial results, and clinical advancements. However, increased operating expenses and limited visibility on the LDO rollout present challenges.View all CRMD earnings summariesCRMD Stock 12 Month Forecast
Average Price Target
$19.50
▲(43.81% Upside)
Technical Analysis
Akebia Therapeutics
―
Kura Oncology
―
Urogen Pharma
―
Bicycle Therapeutics
―
Opthea Limited Sponsored ADR
―
Ownership Overview
2.01% Insiders
8.54% Mutual Funds
10.16% Other Institutional Investors
69.13% Public Companies and Individual Investors